Power Law company profile

CTI Biopharma (Formerly Cell Therapeutics)

Biotech & Life Sciences · Seattle, United States · Founded 1992 · IPO 1997 Unicorn

CTI BioPharma | Seeking to Bring New Options to Patients with Blood Cancers

Valuation

$1.19B

Market cap · 2026

Revenue

$54M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Global footprint

Where CTI Biopharma (Formerly Cell Therapeutics) has talent and traffic

Workforce by country

4 countries with
team presence

🇺🇸 United States88.6%

🇮🇹 Italy5.7%

🇨🇳 China2.8%

🇻🇳 Vietnam2.8%

4 countries shown

Web traffic by country

730 monthly visits
across markets

🏳️ Russian Federation95.9%

Top 1 markets shown

Patent intelligence

$11M patent portfolio · 8 active families

Estimated portfolio value

$11M

0.95% of market cap · 178.4× smaller than top peer Ablynx ($2B)

8 active patent families

Where CTI Biopharma (Formerly Cell Therapeutics) innovates Molecular biologyMedicinal chemistryPhosphatidic acidAmino radicalDisease

Where CTI Biopharma (Formerly Cell Therapeutics) concentrates vs peers

Each axis is a top-10 topic across CTI Biopharma (Formerly Cell Therapeutics) and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about CTI Biopharma (Formerly Cell Therapeutics)

An AI-synthesized read of the highest-engagement posts about CTI Biopharma (Formerly Cell Therapeutics) on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See CTI Biopharma (Formerly Cell Therapeutics) on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles